不同强化时间瑞舒伐他汀对高龄冠心病患者血脂及安全性探究.docVIP

不同强化时间瑞舒伐他汀对高龄冠心病患者血脂及安全性探究 　【摘要】 目的 观察不同强化时间瑞舒伐他汀对高龄冠心病患者降脂疗效和安全性。方法 对60例高龄冠心病患者(年龄gt;70岁)，给予瑞舒伐他汀(可定)10mg，每天1次，检测治疗前及治疗2周、4周后的血脂水平，记录4周内所发生的事件。结果 治疗2周后，血脂水平的变化与治疗前比较总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)有所下降，差异有显著性(Plt;0.01)，高密度脂蛋白胆固醇(HDL-C)有所升高，差异有显著性(Plt; 0.01);治疗4周后，与治疗前比较，TC、TG、LDL-C均明显下降，差异有显著性(Plt; 0.01)，HDL-C有所升高, 差异有显著性(Plt; 0.01)。治疗4周后与治疗2周TC、TG、LDL-C比较，差异有显著性(Plt; 0.01)，HDL-C升高，差异有显著性(Plt;0.01)。结论 应用瑞舒伐他汀治疗高龄冠心病患者，每天10mg，更能有效的使TC、TG、LDL-C达标，无明显不良反应。 【关键词】 冠心病;高龄;血脂;瑞舒伐他汀 　　【Abstract】 Objective To investigate the effect and secutity of different duration of Liprevil for old people with coronary artery disease.Methods Total 60 older people (average age gt;70) with coronary disease were recruited and treated with Liprevil 10mg per day. The levels of plasmic lipoproteins before, after 2 weeks, and after 4 weeks of treatment were measured. All events related to treatment were recorded in 4 weeks. Results The levels of plasmic lipoprotein after 2 weeks? Liprevil treatment including total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) decreased significantly and the level of high-density lipoprotein cholesterol (HDL-C) increased significantly as compared with those before treatment (Plt;0.01). The effect was also significant after 4 weeks’ treatment (Plt;0.01). The difference between 2 and 4 weeks’ treatment was significant as well (Plt;0.01). Conclusion The plasmic lipoproteins including TC, TG, and LDL-C in older people with coronary artery disease could be controlled effectively by treatment of Liprevil 10mg per day complicated with no severe side effect. 　　【Key words】 coronary artery disease; old people; lipoprotein; Liprevil 　　经研究证实，血脂异常是冠心病重要的危险因素之一，应用他汀类药物可降低炎症反应，改善内皮功能，稳定斑块，抑制血栓形成等，可显著降低心血管事件的发生[1]，瑞舒伐他汀(可定)是肝脏羟甲基戊二酰辅酶A(HMG-COA)还原酶的竞争性抑制剂，肝脏选择性更好，药物相互作用少，消除半衰期长，可每日给药1次，药理活性无时辰差异。由此，笔者对高龄冠心病患者使用可定治疗，对其疗效及安全性进行评价。 　　1 对象与方法 　　1.1 对象资料 60例患者，均为青岛市立医院心内科2007年9月—2008年7月的住院患者，年龄gt;70岁，男 30例，女30例。符合以下条件之一：(1) 曾有明确的心肌梗死病史;(2)冠